ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: a case report and review of the literature
Clicks: 166
ID: 242708
2017
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a “real life” situation.
| Reference Key |
annalisa2017leukemiaibrutinib
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Arcari Annalisa;Bassi Simona;Pochintesta Lara;Trabacchi Elena;Moroni Carlo Filippo;Rossi Angela;Zanlari Luca;Vallisa Daniele |
| Journal | urology annals |
| Year | 2017 |
| DOI | 10.1016/j.lrr.2017.11.001 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.